Prof Paul Rolan
Prof Paul Rolan
Verified email at adelaide.edu.au
TitleCited byYear
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agersø, LB Jensen, B Elbrønd, P Rolan, M Zdravkovic
Diabetologia 45 (2), 195-202, 2002
5472002
Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.
J Soul-Lawton, E Seaber, N On, R Wootton, P Rolan, J Posner
Antimicrobial agents and chemotherapy 39 (12), 2759-2764, 1995
3161995
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
B Elbrønd, G Jakobsen, S Larsen, H Agersø, LB Jensen, P Rolan, J Sturis, ...
Diabetes Care 25 (8), 1398-1404, 2002
3052002
Plasma protein binding displacement interactions—why are they still regarded as clinically important?
PE Rolan
British journal of clinical pharmacology 37 (2), 125-128, 1994
2791994
Reduction of metformin renal tubular secretion by cimetidine in man.
A Somogyi, C Stockley, J Keal, P Rolan, F Bochner
British journal of clinical pharmacology 23 (5), 545-551, 1987
2671987
Cortical hyperexcitability is cortical under‐inhibition: evidence from a novel functional test of migraine patients
JE Palmer, EP Chronicle, P Rolan, WM Mulleners
Cephalalgia 20 (6), 525-532, 2000
1282000
Examination of some factors responsible for a food‐induced increase in absorption of atovaquone.
PE Rolan, AJ Mercer, BC Weatherley, T Holdich, H Meire, RW Peck, ...
British journal of clinical pharmacology 37 (1), 13-20, 1994
1251994
The contribution of clinical pharmacology surrogates and models to drug development—a critical appraisal
P Rolan
British journal of clinical pharmacology 44 (3), 219-225, 1997
1101997
Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain
PM Grace, PE Rolan, MR Hutchinson
Brain, behavior, and immunity 25 (7), 1322-1332, 2011
1002011
Reliability of temporal summation and diffuse noxious inhibitory control
S Cathcart, AH Winefield, P Rolan, K Lushington
Pain Research and Management 14 (6), 433-438, 2009
992009
Pharmacokinetics of valsartan in patients with liver disease
LJ Brookman, PE Rolan, IS Benjamin, KR Palmer, PJ Wyld, P Lloyd, ...
Clinical Pharmacology & Therapeutics 62 (3), 272-278, 1997
981997
Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease
P Rolan, MR Hutchinson, KW Johnson
Expert opinion on pharmacotherapy 10 (17), 2897-2904, 2009
912009
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men
P Rolan, ML Sargentini‐Maier, E Pigeolet, A Stockis
British journal of clinical pharmacology 66 (1), 71-75, 2008
912008
Noxious inhibition of temporal summation is impaired in chronic tension‐type headache
S Cathcart, AH Winefield, K Lushington, P Rolan
Headache: The Journal of Head and Face Pain 50 (3), 403-412, 2010
892010
The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males
ML Sargentini‐Maier, P Rolan, J Connell, D Tytgat, T Jacobs, E Pigeolet, ...
British journal of clinical pharmacology 63 (6), 680-688, 2007
862007
Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development
P Rolan, AJ Atkinson, LJ Lesko
Clinical Pharmacology & Therapeutics 73 (4), 284-291, 2003
792003
Stress and tension-type headache mechanisms
S Cathcart, AH Winefield, K Lushington, P Rolan
Cephalalgia 30 (10), 1250-1267, 2010
742010
Central mechanisms of stress‐induced headache
S Cathcart, J Petkov, AH Winefield, K Lushington, P Rolan
Cephalalgia, no-no, 2009
692009
Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90)
P Rolan
Cephalalgia 17 (18_suppl), 21-27, 1997
671997
The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90)
E Seaber, RM Dixon*, M Gibbens, WJ Leavens, J Liptrot, G Chittick, ...
British journal of clinical pharmacology 43 (6), 579-587, 1997
661997
The system can't perform the operation now. Try again later.
Articles 1–20